Khaberni - Sidra Medicine in Qatar announced a medical achievement represented by the availability of the treatment «Sepiapterin» for patients diagnosed with «Phenylketonuria» thereby making Qatar the third country in the world after Germany and the United States to offer this treatment through approved and regulated clinical and governance pathways.
This accomplishment follows the successful administration of «Sepiapterin» to a 12-year-old Qatari girl diagnosed with Phenylketonuria (PKU), a rare inherited metabolic disorder that prevents the body from breaking down the amino acid phenylalanine.
Professor Tawfiq bin Imran, Head of Genetics and Genomic Medicine at Sidra Medicine, stated that making Sepiapterin available for Phenylketonuria patients represents a qualitative step in the care of metabolic disorders as this treatment has the ability to reduce the long-term burden of strict adherence to dietary regimens, and to improve the quality of life for children and adults affected. On his part, Dr. Ahmad Al Hammadi, Head of Pediatrics at Sidra Medicine, stated that this achievement reflects the leading role that Sidra Medicine plays in the care of rare pediatric diseases, and confirms Qatar's role as a regional center for advanced medical treatments.
He noted that providing this treatment through strict clinical governance pathways reflects Sidra Medicine’s commitment to ensuring children and their families receive world-class care within Qatar.
